AstraZeneca’s first-in-class FDA approval for Truqap marred by surprise restriction – FiercePharma November 17, 2023
After 2 FDA rejections and restructuring drive, Intercept sells itself to Italy’s Alfasigma – FiercePharma September 26, 2023
Pfizer’s Talzenna snags broader prostate cancer nod than AstraZeneca and Merck’s rival PARP med – FiercePharma June 21, 2023
ASCO: Seagen’s top-selling drug under threat as Bristol Myers’ Opdivo beats Adcetris in lymphoma – FiercePharma June 4, 2023
Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years – FiercePharma March 17, 2023
With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease – FiercePharma February 17, 2023